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ABSTRACT
Background: Energy expenditure prediction equations are used
to estimate energy intake based on general population measures.
However, when using equations to compare with a disease cohort
with known metabolic abnormalities, it is important to derive one’s
own equations based on measurement conditions matching the
disease cohort.
Objective: We aimed to use newly developed prediction equations
based on a healthy pediatric population to describe and predict resting
energy expenditure (REE) in a cohort of pediatric patients with
thyroid disorders.
Methods: Body composition was measured by DXA and REE
was assessed by indirect calorimetry in 201 healthy participants. A
prediction equation for REE was derived in 100 healthy participants
using multiple linear regression and z scores were calculated. The
equation was validated in 101 healthy participants. This method was
applied to participants with resistance to thyroid hormone (RTH)
disorders, due to mutations in either thyroid hormone receptor β or
α (β: female n= 17, male n= 9; α: female n= 1, male n= 1), with
deviation of REE in patients compared with the healthy population
presented by the difference in z scores.
Results: The prediction equation for REE= 0.061 ∗ Lean soft tissue
(kg) − 0.138 ∗ Sex (0 male, 1 female) + 2.41 (R2 = 0.816). The
mean ± SD of the residuals is −0.02 ± 0.44 kJ/min. Mean ± SD
REE z scores for RTHβ patients are−0.02± 1.26. z Scores of−1.69
and−2.05 were recorded in male (n = 1) and female ( n = 1) RTHα
patients.
Conclusions:We have described methodology whereby differences
in REE between patients with a metabolic disorder and healthy
participants can be expressed as a z score. This approach also enables
change in REE after a clinical intervention (e.g., thyroxine treatment
of RTHα) to be monitored. Am J Clin Nutr 2019;00:1–6.
Keywords: healthy boys and girls, resistance to thyroid hormone,
dual-energy X-ray absorptiometry, indirect calorimetry, resting
energy expenditure prediction equations
Introduction
Predicting resting energy expenditure (REE) can be useful in,
for example, assessing nutritional energy intake requirements in
healthy subjects or patients, in circumstances where expertise
or facilities to measure it accurately are not available. The
most common published prediction equations used in a pediatric
setting are by Schofield (1), Henry (2), Harris and Benedict (3),
andMolnar et al. (4). These equations are based on characteristics
such as age, sex, height, and weight and are derived from large
diverse cohorts, often with pooled data (5, 6). Many studies
have reported inaccuracies of current REE prediction equations
based on traditional height and weight measurements, across
a variety of ages, ethnicities, and disease populations (7–11).
The most recent published equations based on body composition
measurements relevant to the healthy childhood age range include
those of Muller et al. (5), which derive coefficients from fat-free
mass (FFM), fat mass (FM), and sex and explain 72% of the
Supported by theNational Institute for Health Research (NIHR)Cambridge
Clinical Research Facility, Cambridge, United Kingdom (to LPEW, KSC
and PRM), Wellcome Trust grant 095564/Z/11/Z and the NIHR Cambridge
Biomedical Centre (to KC and CM), and Medical Research Council
Elsie Widdowson Laboratory program numbers Physiological Modelling of
Metabolic Risk, MC_UP_A090_1005, and Nutrition, Surveys and Studies,
MC_U105960384 (to MCV).
Data described in the article, code book, and analytic code will be made
available upon request pending application and approval.
Supplemental Figure 1 is available from the “Supplementary data” link in
the online posting of the article and from the same link in the online table of
contents at https://academic.oup.com/ajcn/.
Address correspondence to MCV (e-mail: michelle.venables@mrc-
epid.cam.ac.uk).
Abbreviations used: BM, bone mass; CRF, Clinical Research Facility;
FFM, fat-free mass; FM, fat mass; LST, lean soft tissue; REE, resting energy
expenditure; RTH, resistance to thyroid hormone; TH, thyroid hormone; TR,
thyroid hormone receptor.
Received July 4, 2018. Accepted for publication July 10, 2019.
First published online 0, 2019; doi: https://doi.org/10.1093/ajcn/nqz177.
Am J Clin Nutr 2019;00:1–6. Printed in USA. Copyright © American Society for Nutrition 2019. All rights reserved. This is an Open Access article distributed
under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution,











nit user on 11 O
ctober 2019
2 Watson et al.
variance. However, these data are based on observations pooled
from separate German databases collected over a period of 18 y
and may not be appropriate for other geographical populations or
their associated disease groups.
Metabolic disorders are often associated with altered body
composition (12). Adult patients with disorders such as thyrotox-
icosis, resistance to thyroid hormone (RTH), and lipodystrophy
have previously been shown to exhibit differences in both body
composition and energy expenditure (13–16) compared with
healthy controls (12). These disorders are also prevalent in
childhood but diagnosed more rarely.
RTHβ, a genetic disorder due to mutations in the thyroid
hormone receptor (TR) β gene, is characterized by elevated
circulating thyroid hormones (THs), nonsuppressed thyroid
stimulating hormone concentrations, and variable resistance
to hormone action in peripheral tissues. The clinical features
of RTHβ are highly variable, with most individuals being
asymptomatic in a compensated euthyroid state, whereas a subset
exhibit features (e.g., tachycardia and weight loss) reflecting
hyperthyroidism of TRα-expressing tissues. This unpredictable
clinical phenotype makes management of RTHβ in childhood
difficult (17). Mutations in TRα causing RTHα are rare, with
30 patients from 17 families having been reported worldwide,
13 of whom were children. The clinical features of RTHα
(growth retardation and developmental delay) resemble those in
untreated childhood hypothyroidism (18, 19), reflecting hormone
resistance and a relative hypothyroid state in TRα-expressing
tissues.
After diagnosis, TH (thyroxine) therapy is used to alleviate
hypothyroid features in RTHα. Conversely, in RTHβ, treatment
with triiodothyroacetic acid, a TH analog which acts centrally
to reduce hormone concentrations but is relatively devoid of
thyromimetic effects in peripheral tissues, is used to control pe-
ripheral features of thyrotoxicosis. In both disorders, biochemical
markers are monitored frequently to assess treatment, but the role
of serial physiological measurements (e.g., energy expenditure
and body composition) in children with RTH has not yet been
evaluated.
The aim of this research was to demonstrate the use of newly
developed prediction equations for REE in healthy participants
for the purpose of describing differences in REE between healthy
participants and participants with a metabolic disorder (RTH
patient cohort) by computation of a z score.
Methods
Participants
Two hundred and one healthy male and female participants
aged between 6 and 16 y and free from disease and medications
took part in the study between July 2014 and December 2016 (see
Supplemental Figure 1 for the participant flowchart). Twenty-
five participants with RTHβ were recruited between August 2006
and April 2016 and 2 participants with RTHα were recruited and
followed up between October 2010 and February 2017. After
reading the relevant information leaflets and having the study
fully explained, the participants then assented and parents con-
sented to taking part in the study. The healthy participants were
recruited locally through advertisements including radio and
ethical approval was granted by the East of England–Cambridge
South ethics committee (14/EE/092) and the Research and
Development department at Addenbrooke’s hospital (A093198)
in Cambridge. Participants with RTHwere recruited after referral
to the Endocrine clinic, Addenbrooke’s hospital, with metabolic
measurements being conducted under either clinical auspices
or a research protocol [ethical approval was granted by East
of England–Cambridge Central ethics committee (98/154) and
the Research and Development department at Addenbrooke’s
hospital (A06658) in Cambridge].
Body composition
All participants arrived at the National Institute for Health
Research Cambridge Clinical Research Facility (CRF) in the
afternoon having eaten lunch. On arrival and after the con-
sent process, the participants underwent clinical measurements
including blood pressure, temperature, and electrocardiogram.
Height was measured on a stadiometer and recorded to the
nearest millimeter (SECA electronic stadiometer) andweight was
measured on electronic scales to the nearest gram (Kern & Sohn
GmbH).
The participants then completed a whole body DXA assess-
ment for bone mass (BM) and body composition [FM and lean
soft tissue (LST)] (GE iDXA, analyzed in version 16, enhanced
mode).
REE
The participants stayed overnight at the CRF, Cambridge.
Theywere fed an energy-balancedmeal at their usual dinner time,
based on the Schofield (1) predictions for energy expenditure.
Usual bedtimes and waking times for each participant were
adhered to.
REE was measured 30 min after waking by indirect calorime-
try using a ventilated hood (GEM Nutrition). The participants
were asked to remain still, awake, and not interact with others
for 40 min during the measurements. Gas measurements of the
room were made for the first 10 min, followed by the ventilated
hood measurement of the participant for 20 min with a further
10 min of room gas analysis at the end of the measurement.
The room measurements were to account for any apparent gas
exchange which might arise in the absence of the participant
from changes in room air composition after the initial room air
sample. The gas exchange measurements were then converted
into energy equivalents using calculations by Elia and Livesey
(20). Before each measurement, the calorimeter was calibrated
using 1% carbon dioxide and 20.9% oxygen. Annually the
indirect calorimeters undergo 3 types of quality assurance tests: a
flow rate tolerance test (reading within 2% of the measured flow
rate), an infusion of N2 and carbon dioxide respiratory quotient
of 0.85 test (ranging from 0.84 to 0.9), and a tolerance of drying
tube test (effectiveness reading + 15 mL/min V˙O2). Repeated
measurements of REE using our GEM Nutrition instruments
demonstrate a CV of 3.8% and least significant change of
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TABLE 1 Descriptive characteristics for the regression model cohort and the validation cohort1
Age, y
Regression model cohort (n = 100) Validation cohort (n = 101)
6–8 9–11 12–14 15–16 6–8 9–11 12–14 15–16
(n = 10 M, 14 F) (n = 11 M, 20 F) (n = 11 M, 13 F) (n= 15 M, 6 F) (n= 7 M, 13 F) (n = 19 M, 18 F) (n= 9 M, 16 F) (n= 12 M, 7 F)
Age, y 7.6 ± 0.9 10.5 ± 0.8 13.4 ± 1.0 15.9 ± 0.7 7.4 ± 0.8 10.3 ± 0.9 13.3 ± 1.0 16.0 ± 0.7
Height, m 1.26 ± 0.06 1.43 ± 0.07 1.61 ± 0.09 1.73 ± 0.08 1.27 ± 0.10 1.45 ± 0.10 1.63 ± 0.08 1.75 ± 0.09
Weight, kg 27.3 ± 5.1 36.4 ± 7.2 48.7 ± 8.2 60.9 ± 8.8 26.0 ± 4.1 39.2 ± 10.2 50.9 ± 8.8 63.9 ± 10.2
BMI, kg/m2 17.2 ± 2.3 17.8 ± 2.6 18.8 ± 2.6 20.2 ± 2.0 16.2 ± 2.0 18.4 ± 3.1 19.2 ± 2.4 21.0 ± 3.9
FM, kg 7.8 ± 3.1 10.7 ± 4.3 12.2 ± 4.2 13.1 ± 4.7 7.1 ± 2.0 11.6 ± 5.4 13.6 ± 4.6 15.2 ± 7.3
LST, kg 18.6 ± 2.5 24.6 ± 3.6 34.8 ± 5.9 45.6 ± 7.8 18.3 ± 3.0 26.4 ± 5.6 35.7 ± 6.3 46.6 ± 8.4
BM, kg 0.97 ± 0.15 1.34 ± 0.23 1.91 ± 0.39 2.51 ± 0.44 0.97 ± 0.13 1.40 ± 0.30 2.00 ± 0.41 2.60 ± 0.30
REE, kJ/min 3.41 ± 0.35 3.92 ± 0.42 4.44 ± 0.50 5.07 ± 0.73 3.31 ± 0.51 4.09 ± 0.62 4.54 ± 0.63 4.93 ± 0.81
1Values are means ± SDs. BM, bone mass; FM, fat mass; LST, lean soft tissue; REE, resting energy expenditure.
Statistical analysis
Data are reported as means ± SDs. Nonparametric tests
were used throughout the analysis. Spearman correlations were
determined between all variables (height, weight, age, BMI, FM,
LST, BM) and REE. Stepwise multiple regression analysis was
conducted to develop a prediction equation for REE. The Mann–
Whitney U test was used to determine significant difference
in distribution and variables between the regression cohort
and validation cohort. The difference between measured and
predicted REE is described as the residual. When an individual
residual is divided by the SD of all the residuals, this represents
a cohort z score. Although we have not assigned an absolute
threshold for defining whether an individual data point is outside
of the healthy range, if the z score for the patient is ±1, then it
suggests there is a 68% probability that the observation belongs in
the healthy cohort. If the z score is ±2, then the probability falls
to 5%, making it 95% likely that the observation is associated
with a disorder. IBM SPSS Statistics for Windows version 22.0
was used for descriptive statistics, correlations, and regression
analysis. GraphPad Prism version 6 was used for Bland–Altman
analyses.
Results
The total cohort of 201 healthy participants was randomly
divided into a regression data set (n = 100) and a validation
data set (n = 101). Descriptive statistics for both data sets are
presented inTable 1. There were no significant differences in age,
height, weight, BMI, FM, LST, BM, and REE between the model
and validation data sets.
Regression analysis
Regression analysis was performed with REE as the dependent
variable. The predictor variables included those variables that
were significantly correlated with REE in the bivariate analysis.
With REE as the dependent variable, height (r = 0.883,
P < 0.001), age (r = 0.788, P < 0.001), FM (r = 0.464,
P < 0.001), LST (r = 0.896, P < 0.001), and BM (r = 0.864,
P < 0.001) were correlated and entered into the regression anal-
ysis. After stepwise elimination of nonsignificant contributors
to the regression, the results showed that there were 2 models
that significantly predicted REE (Table 2). Model 1 included
LST and accounted for 81% of the variation in REE and model
2 included LST and sex which accounted for 81.6% of the
variation: REE = 0.061 ∗ Lean soft tissue (LST) (kg) − 0.138
∗ Sex (0 male, 1 female) + 2.41 (R2 = 0.816).
Prediction model 2 was then applied to the validation cohort
(n = 101), showing a significant correlation with measured REE
(r = 0.850, P < 0.001).
The mean± SD (95% CI) of the difference between measured
and predicted REE was −0.02 ± 0.44 (−0.10, 0.07) kJ/min. The
agreement between the measured REE and the predicted REE is
presented by the Bland–Altman plot in Figure 1.
Clinical application
Clinical and biochemical characteristics for RTHβ and RTHα
participants are presented in Table 3.
The prediction equation (model 2) was then applied to par-
ticipants with RTH disorders before treatment. The mean ± SD
(95% CI) of the difference between measured and predicted REE
TABLE 2 Stepwise regression coefficients based on n = 100 for the prediction of resting energy expenditure1
Model Variable Coefficient SE Adjusted R2 Sig F Change 95% CI
1 LST 0.063 0.003 0.810 0.000 0.056, 0.069
Constant 2.288 0.097 2.095, 2.481
2 LST 0.061 0.003 0.816 0.047 0.055, 0.067
Sex –0.138 0.069 –0.274, –0.002
Constant 2.410 0.113 2.185, 2.634
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FIGURE 1 Bland–Altman agreement between measured and predicted
REE in 101 healthy participants. Limits of agreement: −0.89 to 0.86; bias
(mean ± SD): −0.02 ± 0.44. REE, resting energy expenditure.
(residuals) for RTHβ was −0.01 ± 0.55 (−0.24, 0.22) kJ/min.
The RTHα participants exhibited lower energy expenditure for
both the male and the female participants (difference: −0.75 kJ/
min and −0.90 kJ/min, respectively) (Figure 2).
z Scores were then applied to the RTH cohorts based on the SD
of the residuals derived from the healthy validation cohort (0.44).
The mean ± SD z score for the RTHβ cohort was −0.02 ± 1.26.
For the male and the female RTHα participant the z score was
−1.69 and −2.05, respectively.
Figure 3 shows the use of the prediction equations in
monitoring serial changes in REE in individual male and female
RTHα patients after thyroxine treatment, in comparison with
healthy participants. For the male, at the age of 15 y, before
treatment, the REE z score was −1.69 (mean difference −0.75
kJ/min), changing to −1.11 at age 16 y and −2.26 at 17 y
(thyroxine dosage, 62.5 μg/d), after thyroxine therapy. For the
female RTHα patient, the baseline REE z score at age 5 y, before
thyroxine treatment, was −2.05. During thyroxine therapy (age
6–14 y), the REE z score changed, with values at ages 7 and
8 y being closest to zero (z score: −0.25 and −0.73; thyroxine
dosage 87.5 μg/d) and from the age of 11 to 14 y reducing
FIGURE 2 Residuals (mean ± SD) of measured and predicted REE and
corresponding z scores for healthy (0.02 ± 0.44), RTHβ (−0.02 ± 1.26),
and RTHα (male: −1.69; female: −2.05) groups. REE, resting energy
expenditure; RTH, resistance to thyroid hormone.
from −1.13 to −1.92, prompting further increases in thyroxine
(125–150 μg/d).
Discussion
The primary aim of this research was to develop prediction
equations for REE in healthy participants aged 6–16 y, for
the purpose of describing normal and disordered REE by the
application of a z score in healthy individuals and also a cohort
of RTH patients. The novelty of the concept lies in the derivation
and application of a z score in an energy expenditure context.
We described such an approach previously in an adult population
(12), but its application to a pediatric population had not been
evaluated hitherto, to our knowledge.
Typically, REE prediction equations have been derived based
on specific populations of interest (e.g., children, obese, elderly,
or disease groups) (7–11). Their purposes have been either for
assessing energy intake requirements or for explaining changes
in body composition such as weight loss or gain. This study
proposes the use of prediction equations to describe and quantify
TABLE 3 Descriptive characteristics of RTHβ and RTHα patients1
RTHβ RTHα
Male (n = 8) Female (n = 17) Male (n = 1) Female (n = 1)
Height, m 1.39 ± 0.16 1.39 ± 0.19 1.52 0.99
Weight, kg 27.5 ± 8.7 39.8 ± 21.9 49.2 22.7
BMI, kg/m2 14.1 ± 2.2 19.5 ± 7.1 20.5 23.5
Age, y 10.7 ± 2.9 10.6 ± 3.8 15.5 5.8
FM, kg 3.7 ± 2.8 13.6 ± 12.5 8.4 4.6
LST, kg 22.7 ± 6.6 24.8 ± 9.4 39.1 17.5
BM, kg 1.1 ± 0.4 1.4 ± 0.8 1.7 0.7
TSH, mU/L (RR: 0.35–5.5) 3.3 ± 1.07 3.4 ± 1.07 2.07 1.04
FT4, pmol/L (RR: 9.01–22.7) 51.7 ± 30.2 46.1 ± 30.2 8.4 5.7
FT3, pmol/L (RR: 2.63–7.6) 19.1 ± 7.67 17.8 ± 7.67 9.1 6.9
REE, kJ/min 3.62 ± 0.55 3.86 ± 1.06 3.98 2.40
1Normal RRs are based on age. BM, bone mass; FM, fat mass; FT3, triiodothyronine; FT4, thyroxine; LST, lean soft tissue; REE, resting energy
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FIGURE 3 Residuals of measured and predicted REE and corresponding z scores at baseline and after treatment with thyroxine at the dosage (micrograms
per day) indicated, in an individual male (left) and female (right) RTHα patient, compared with the healthy control cohort. REE, resting energy expenditure;
RTH, resistance to thyroid hormone.
deviation of REE in metabolic disorders from this physiological
parameter in a healthy population.
Our prediction equations show that LST and sex are significant
predictors explaining 81.6% of the variance in REE. Goran et al.
(21) and Muller et al. (5) have also shown these variables to be
determinants of REE, explaining 63% and 72% of the variation in
REE in healthy nonobese children, respectively. When applying
the Muller et al. equation to our validation data set, we observed
a significant 10-fold difference in the mean ± SD residuals
(0.27 ± 0.43 kJ/min compared with −0.02 ± 0.44 for Muller et
al. and Watson et al., respectively). We would, however, expect
there to be differences between the 2 prediction equations for 2
reasons; firstly, Muller et al. were only able to explain 72% of the
variation in REE in 243 children, whereas our prediction equation
explained 82% of the variation in 100 children. Secondly, there
are methodological differences in the way REE data were
collected.
One aim of generating childhood prediction equations was
to apply them to metabolic disorders. The prediction equations
were applied to disorders of TH action to describe the magnitude
of difference in REE in patients compared with a healthy
population. This approach has previously been used in adults
(12), where thyrotoxic, lipodystrophic, and RTHβ patients all
showed elevated energy expenditure z scores. Similarly, this
study has identified differences in REE in 2 disorders, RTHβ
and RTHα, in childhood. In RTHβ, patients showed a normal
mean z score (−0.02) for REE, consistent with a compensated
euthyroid state. In a previous study using published prediction
equations (3, 4), Mitchell et al. (13) showed that REE was
elevated ≤20% higher than predicted in both adults and children
with RTHβ. The known phenotypic variability of RTHβ, with
patients with differing degrees of resistance in peripheral tissues
being recruited to each of these cohorts, may account for
the observed difference in predicted REE in RTHβ between
the 2 studies. In RTHα patients, low REE z scores (male
z score: −1.69; female z score: −2.05) were documented,
correlating with the known hypothyroid phenotype of the
disorder and in agreement with observations reported previously
(19, 22).
This study also illustrates the value of serial prediction
equation–based measurements in individual patients with dis-
ordered metabolism. Treatment of a patient with conventional
hypothyroidism with thyroxine would be expected to improve
thyroid status and therefore increase REE. Serial measurement
of REE z scores can provide an indirect assessment of the
efficacy of thyroxine therapy. Advantages of depicting serial REE
measurements as a z score, rather than as absolute values, are that
REE has been adjusted for changes in body composition and is
also compared with a matched healthy participant group.
Several limitations of this study should be considered. Firstly,
for some age groups, the sample size was small. To apply the
equations with confidence across the entire 6–16 y age range,
larger sample sizes need to be studied. Secondly, this study did
not assess a pubertal contribution to REE, whereas previously
published prediction equations have shown an effect of pubertal
stage (23). Lazzer et al. (24) proposed 2 REE prediction equations
in obese children based on body mass or body composition. Their
body composition equation was determined by the variables
FFM, FM, sex, and pubertal stage using Tanner and Marshall
scales (R2 = 0.70) (25, 26). The inclusion of pubertal stage
in relation to REE by Lazzer et al. emphasizes the importance
of using pubertal status rather than chronological age when
investigating children with atypical body composition or REE.
In summary, body composition and REE have been described
in a cohort of healthy participants and patients aged 6–
16 y. Prediction equations for REE were developed using a
healthy cohort, with z scores calculated in patients with rare
disorders of TH action. Such novel use of REE z scores may
facilitate assessment of energy expenditure inmetabolic disorders
and enable monitoring of responses to therapeutic or other
intervention.
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